Ignite Creation Date:
2025-12-25 @ 2:17 AM
Ignite Modification Date:
2026-02-24 @ 12:25 AM
Study NCT ID:
NCT02652260
Status:
COMPLETED
Last Update Posted:
2025-02-07
First Post:
2016-01-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-03-04
Start Date Type:
ACTUAL
Primary Completion Date:
2018-08-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-02-07
Completion Date Type:
ACTUAL
First Submit Date:
2016-01-08
First Submit QC Date:
None
Study First Post Date:
2016-01-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-07-16
Results First Submit QC Date:
None
Results First Post Date:
2019-08-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-01-21
Last Update Post Date:
2025-02-07
Last Update Post Date Type:
ACTUAL